Treatment-related hearing loss in weekly versus triweekly cisplatin chemoradiation for head and neck cancer
Cisplatin-dose reduction to a weekly cisplatin CRT regimen for head and neck cancer may reduce the incidence of clinically relevant hearing loss at frequencies vital for speech perception.
Authors
- Katarzyna Jóźwiak (ORCID: https://orcid.org/0000-0002-9614-6586)
- Cris Lanting (ORCID: https://orcid.org/0000-0001-9397-7766)
- Arash Navran (ORCID: https://orcid.org/0000-0001-7006-7807)
- Wouter A. Dreschler (ORCID: https://orcid.org/0000-0002-4192-6104)
- Alfons J. M. Balm (ORCID: https://orcid.org/0000-0001-9935-3217)
- Charlotte L. Zuur (ORCID: https://orcid.org/0000-0002-1777-012X)
- Klaske E. van Sluis (ORCID: https://orcid.org/0000-0002-9288-5402)
- Jan Paul de Boer (ORCID: https://orcid.org/0000-0001-6218-6128)
- Charlotte W. Duinkerken (ORCID: https://orcid.org/0000-0001-9194-6560)
- Anouk V. M. Burger (ORCID: https://orcid.org/0000-0003-0435-3981)
Institutions
- Radboud University Nijmegen (NL)
- Leiden University Medical Center (NL)
- Radboud University Medical Center (NL)
- The Netherlands Cancer Institute (NL)
- Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (NL)
- Medizinische Hochschule Brandenburg Theodor Fontane (DE)
- Amsterdam University Medical Centers (NL)
Publication Details
- Journal
- European Archives of Oto-Rhino-Laryngology
- Published
- 2024-09-06
- DOI
- https://doi.org/10.1007/s00405-024-08880-x
- Citations
- 2
- Primary Topic
- Head and Neck Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.16